α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10
Open accessThe DOI matches its Crossref record.
Abstract
Synovial sarcoma (SS) is a rare yet refractory soft‐tissue sarcoma that predominantly affects young adults. We show in a mouse model that radioimmunotherapy (RIT) with an α‐particle emitting anti‐Frizzled homolog 10 (FZD 10) antibody, synthesized using the α‐emitter radionuclide astatine‐211 (211 At‐OTSA 101), suppresses the growth of SS xenografts more efficiently than the corresponding β‐particle emitting anti‐FZD 10 antibody conjugated with the β‐emitter yettrium‐90 (90 Y‐OTSA 101). In biodistribution analysis, 211 At was increased in the SS xenografts but decreased in other tissues up to 1 day after injection as time proceeded, albeit with a relatively higher uptake in the stomach. Single 211 At‐OTSA 101 doses of 25 and 50 μCi significantly suppressed SS tumor growth in vivo, whereas a 50‐μCi dose of 90 Y‐OTSA 101 was needed to achieve this. Importantly, 50 μCi of 211 At‐OTSA 101 suppressed tumor growth immediately after injection, whereas this effect required several days in the case of 90 Y‐OTSA 101. Both radiolabeled antibodies at the 50‐μCi dosage level significantly prolonged survival. Histopathologically, severe cellular damage accompanied by massive cell death was evident in the SS xenografts at even 1 day after the 211 At‐OTSA 101 injection, but these effects were relatively milder with 90 Y‐OTSA 101 at the same timepoint, even though the absorbed doses were comparable (3.3 and 3.0 Gy, respectively). We conclude that α‐particle RIT with 211 At‐OTSA 101 is a potential new therapeutic option for SS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“In addition, mAbs can serve as the vehicle to achieve precision medicine, such as targeting radiogen to tumors.(275) To sum up, in practical scenarios, mAbs are more competent for the treatment of hematological tumors than solid tumors as a consequence of their antigenicity and large particles.”
BackgroundTargeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”
Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J.-F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060906 · Cited by 196
Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
Applied nuclear physics at the new high-energy particle accelerator facilities
Durante, M., Golubev, A., Park, W.-Y., & Trautmann, C. (2019) · Physics Reports · doi:10.1016/j.physrep.2019.01.004 · Cited by 72
Metadata
- Authors
- Li, H. K., Sugyo, A., Tsuji, A. B., Morokoshi, Y., Minegishi, K., Nagatsu, K., Kanda, H., Harada, Y., Nagayama, S., Katagiri, T., Nakamura, Y., Higashi, T., & Hasegawa, S.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2018-06-27
- Volume
- 109
- Issue
- 7
- Pages
- 2302-2309
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2810888503
- Cited by
- 41
- References
- 0
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10. https://app.cochat.ai/papers/10.1111/cas.13636
- The paper
- Li, H. K., Sugyo, A., Tsuji, A. B., Morokoshi, Y., Minegishi, K., Nagatsu, K., Kanda, H., Harada, Y., Nagayama, S., Katagiri, T., Nakamura, Y., Higashi, T., & Hasegawa, S. (2018). α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10. Cancer Science. https://doi.org/10.1111/cas.13636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.